公开(公告)号：US20180028491A1

公开(公告)日：2018-02-01

申请号：US15659114

申请日：2017-07-25

Applicant: Ausio Pharmaceuticals, LLC

Inventor： Richard L. JACKSON

IPC: A61K31/353 ,  C12Q1/48 ,  C12Q1/68 ,  C12Q1/26

CPC classification number: A61K31/353 ,  C12Q1/26 ,  C12Q1/48 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Y109/03001 ,  C12Y203/03001 ,  G01N2800/2821 ,  G01N2800/50

Abstract: The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.

公开(公告)号：US20210283097A1

公开(公告)日：2021-09-16

申请号：US16320938

申请日：2017-07-25

Applicant: Ausio Pharmaceuticals, LLC

Inventor： Richard L. JACKSON

IPC: A61K31/352 ,  G01N33/68

Abstract: The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.

公开(公告)号：US20160102070A1

公开(公告)日：2016-04-14

申请号：US14883617

申请日：2015-10-14

Applicant: Ausio Pharmaceuticals, LLC

Inventor： Richard L. JACKSON

IPC: C07D311/04

CPC classification number: C07D311/04

Abstract: An anhydrous crystalline form of S-equol has been discovered. Form I, the anhydrous crystalline form of S-equol has been isolated and characterized for the first time. As compared to other forms of S-equol, such as the known hydrate or other solvate forms, the anhydrous crystalline form of S-equol has improved properties.

Abstract translation: 已经发现了S-牛尿酚的无水结晶形式。 形式I，S-牛尿酚的无水结晶形式已经被首次分离和表征。 与其他形式的S-牛尿酚（例如已知的水合物或其它溶剂合物形式）相比，S-牛尿酚的无水结晶形式具有改善的性能。